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Highlights: 
• This is the first tobacco simulation model to consider disparities by mental health 
status. 
• Model projections show that the smoking disparity by depression status will 
persist over time. 
• Smoking prevalence will continue to decline for adults with major depression 
(MD). 
• 484,000 smoking-related deaths will occur among adults with MD from 2018-
2060, with 11.3 million life years lost. 
• At most, interventions could prevent up to 264,000 of these premature deaths, 




Tobacco-related health disparities disproportionately affect smokers with major 
depression (MD). Although tobacco simulation models have been applied to general 
populations, to date they have not considered populations with a comorbid mental 
health condition. We developed and calibrated a simulation model of smoking and MD 
comorbidity for the US adult population using the 2005-2018 National Surveys on Drug 
Use and Health. We use this model to evaluate trends in smoking prevalence, smoking-
attributable mortality and life-years lost among adults with MD, and changes in smoking 
prevalence by mental health status from 2018-2060. The model integrates known 
interaction effects between smoking initiation and cessation, and MD onset and 
recurrence. We show that from 2018-2060, smoking prevalence will continue declining 
among those with current MD. In the absence of intervention, people with MD will be 
increasingly disproportionately affected by smoking compared to the general population; 
our model shows that the smoking prevalence ratio between those with current MD and 
those without a history of MD increases from 1.54 to 2.42 for men and from 1.81 to 2.73 
for women during this time period. From 2018-2060, approximately 484,000 smoking-
attributable deaths will occur among adults with current MD, leading to 11.3 million life-
years lost. Ambitious tobacco control efforts could alter this trajectory. With aggressive 
public health efforts, up to 264,000 of those premature deaths could be avoided, 
translating into 7.5 million life years gained. This model can compare the relative health 






Each year 16.2 million people in the US experience a major depressive episode, 
approximately 6.7% of the population.1 People with major depression (MD) die up to 11 
years earlier than those without MD, driven in part by their high smoking rates.2 In 2017, 
23.5% of people with depression smoked compared to 15% of people without depression, 
and their daily smoking prevalence was nearly twice as high.3 International organizations 
and experts consider smokers with comorbid mental illness such as MD a high priority 
group for tobacco control intervention.4-7  
The relationship between MD and smoking is bi-directional and causal, even after 
adjusting for demographic characteristics and other psychiatric disorders.8-11 MD is a risk 
factor for future smoking, and tobacco use predicts subsequent MD symptoms. Smoking 
cessation decreases depressive symptoms.12 These feedback loops imply that changes 
in MD or smoking could affect the other. To examine the implications of this relationship, 
we consider the potential for MD and smoking to reinforce each other.  
Governments increasingly use simulation models to facilitate public health decision-
making and long-term planning. Numerous models already estimate population tobacco 
use over time.13 To our knowledge, none have considered smoking disparities by mental 
health status. Similarly, existing MD models do not explicitly account for smoking 
comorbidity.14-19 A model of smoking and MD can evaluate the burden of smoking in 
populations with MD and changes to this disparity over time. 
We developed a system dynamics model of smoking and MD comorbidity for the US adult 
population. System dynamics models include stocks of individuals within a health state 
(e.g., people with current MD) and flows characterizing individuals’ movement between 
health states (e.g., MD incidence or recovery). They are ideal for testing macro-level 
changes in systems with nonlinearity, feedback loops (e.g., interactions between smoking 
and MD), and time delays between events (e.g., smoking initiation) and future health 
consequences (e.g., disease and death). We projected smoking prevalence, smoking-
attributable mortality, and life-years lost by MD status from 2018-2060. We also calculated 





We used data from the 2005-2018 National Surveys on Drug Use and Health (NSDUH). 
NSDUH is an annual nationally representative survey of the non-institutionalized 
population of US adults ages ≥18.20 NSDUH is the most historically comprehensive 
national survey to include measures for smoking behaviors and depressive episodes.  
We calibrated separate smoking-only and MD-only sub-models to NSDUH data, and then 
combined both sub-models and their inputs into the full comorbidity model. We re-
calibrated the combined model to fit survey data on smoking prevalence by MD status, 
and vice versa. The full model integrated and estimated known and unknown interaction 
effects between smoking initiation and cessation, and MD onset, relapse and recovery. 
Analyses were conducted using R version 3.1.3.  
Smoking sub-model 
We considered three mutually exclusive smoking states in the smoking sub-model: never 
smoker, current smoker, and former smoker. Current smokers smoked at least 100 
cigarettes in their lifetime and smoked anytime within the past year. Former smokers 
smoked at least 100 cigarettes in their lifetime but have not smoked at any point in the 
last year. This strict definition for current smokers includes those who have quit smoking 
less than one year prior to survey assessment, avoiding the problem of modeling 
cessation relapse by categorizing as former smokers only those who likely have 
permanently quit. Never smokers have smoked fewer than 100 cigarettes in their lifetime. 
These definitions enable the model to be more consistent with input data sources and to 
simulate permanent smoking cessation without relapse. (See Appendix Table S1.)  
Individuals enter the model at birth as never smokers who can become current smokers, 
and then former smokers, based on initiation and cessation probabilities developed by 
the Cancer Intervention and Surveillance Modeling Network (CISNET) lung consortium.21 
Individuals exit the model through death or after age 99. CISNET provides age, gender, 
and birth cohort-specific mortality rates for never smokers, former smokers, and current 
smokers.22 For future projections, CISNET smoking initiation and cessation probabilities 




NSDUH screens adults for lifetime and past year experience of an MD episode using 
criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV); an 
individual must report at least five of nine common depression symptoms for a two-week 
or longer period.24 NSDUH does not exclude MD episodes caused by illness, 
bereavement, substance use or other psychiatric disorders, such as bipolar disorder.25  
For this model, people with current MD have had an MD episode in the past year. Those 
with former MD have had an episode in their lifetime but not in the past year. Those with 
never MD have never had an MD episode. Cross-sectional surveys of depression that 
rely on retrospective evaluations can lead to substantial underestimation of lifetime history 
of depression.26 Therefore, the model explicitly accounts for the probability of recall error 
and misclassification of individuals as some never MD are modeled as former MD. This 
sub-model has been used to analyze the impact of recall error on US patterns of lifetime 
MD.19  
Individuals are born as never MD, and may transition to a first MD episode based on 
incidence data from the Baltimore Epidemiological Catchment Area (ECA) Study,27 the 
nation’s longest-running psychiatric epidemiological cohort study. Since MD incidence 
data for females ages <22 and males ages <29 do not exist, we estimated the annual 
probability of a first MD episode at younger ages as part of calibration using cubic natural 
splines to fit the sub-model to NSDUH data. Individuals may recover from a first MD 
episode and shift into a former MD category. Former MD individuals may also have a 
recurrent MD episode and subsequently recover.28 MD age-specific incidence rates are 
assumed to remain constant into the future, as NSDUH data show no visible trends in 
depression patterns by age for the 2005-2015 period. Due to recall error among those 
with former MD, we report findings for the current and ‘true’ never MD population only; 
results reported for the never MD population are adjusted for recall error by removing 
those who incorrectly self-report as never MD.19 Because recent NSDUH data show that 
MD prevalence has increased among young adults ages 18-25,29 MD incidence 
parameters were increased for this age group in 2016 and held constant thereafter to be 
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conservative. We present an alternative scenario in which MD incidence probabilities 
return to pre-2016 levels in the Appendix. 
MD and smoking comorbidity model 
The combined MD and smoking (MDS) model includes 15 mutually exclusive smoking 
and depressive states (Figure 1) and projects future smoking and MD prevalence for the 
US population ages ≥18. We modeled males and females separately, as females have 
higher risk for depression and earlier ages at onset than males, and males have higher 
smoking and mortality rates compared to females.30,31 
Each cohort is born a never smoker and never MD state using Census Bureau projected 
population sizes.32 We simulated the population through 2060, the final year of population 
estimates available from the Census Bureau, as done in previous simulation studies.32-34 
We initialize the model in year 1900 with the 1900 birth cohort, and new birth cohorts are 
added each year such that by 1999, the model includes the entire population ages 0-99. 
We apply a relative risk of mortality for individuals with histories of MD estimated during 
model calibration to smoking status-specific mortality rates.  
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Figure 1. Major depression and smoking model diagram 
 
Overview of the major depression and smoking model with 15 mutually exclusive smoking and MD compartments. 
Dotted outline = never smoker; solid outline = current smoker; dashed outline = former smoker; white fill = no history 
of MD episode in lifetime; black fill = MD episode within the last year; gray fill = lifetime history of at least 1 MD 
episode but none in the past year; diagonal cross-hatch = history of at least 1 MD episode. 
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To calibrate the sub-models and full model, we minimized the sum of squared differences 
between the proportions of individuals in age, smoking, and MD categories observed in 
the NSDUH and the model predictions using the Davidon-Fletcher-Powell optimization 
algorithm in the Bhat package in R.35 Given initial model parameter values and their 
corresponding upper and lower limits, the algorithm searches the parameter space for 
estimates of scaling factors and interaction effects between smoking and depression that 
enable the model to reproduce observed smoking and depression patterns by age group. 
The calibration process refined existing parameter estimates and generated plausible 
values that do not otherwise exist in the literature, such as depressive episode recovery 
rates by smoking status. Where possible, we drew initial values used in the optimization 
from the literature.  
Input parameters used in the model, including the smoking and MD sub-models appear 
in Appendix Table S2. Parameters for interaction effects assumed that current and former 
smokers have equal or higher MD onset and recurrence rates and equal or lower recovery 
rates compared to never smokers. We re-estimated effects of depression on smoking 
behaviors such that those with current MD had increased probability of smoking initiation 
and lower odds of cessation. To evaluate the sensitivity of model outcomes to each of the 
interaction effect estimates derived from calibration, we conducted Latin Hypercube 
Sampling (LHS) and report these results as uncertainty ranges. See Appendix. 
Smoking-attributable mortality 
To assess smoking-attributable mortality, we sum smoking-attributable deaths (𝑆𝐴𝐷) for 
former smokers and current smokers across all ages and both genders. We calculate 
total deaths by multiplying the current and former smoker prevalences (𝑝𝑟𝑒𝑣𝑐𝑠, 𝑓𝑠) by the 
corresponding population sizes (𝑃) for each age group and gender, and by the difference 
in mortality rates between current or former smokers and never smokers (𝜇𝑐𝑠,𝑓𝑠,𝑛𝑠) as 
follows36:  





This equation determines the number of deaths attributable to current and former smoking 
for a given population. Total years of life lost (YLL) take each former or current smoker 
death at a given age, and apply remaining never smoker life expectancy at those ages 
(𝑒𝑛𝑠,𝑎,𝑔 × 𝑆𝐴𝐷𝑎,𝑔).
36 We report prevalence data comparing the population with current and 
never MD (excluding recall error) to assess differences between the two most disparate 
groups. This calculation excludes deaths due to secondhand smoke exposure. Of all 
smoking-attributable deaths and years of life lost among the comorbid population, we 
furthermore calculate the number that could be completely avoided under a maximum 
potential reduction in premature mortality (MPRPM) scenario37, in which all smokers with 




Following calibration, the full MDS model demonstrated a close fit with corresponding 
NSDUH 2005-2018 estimates of smoking in the adult current and never MD populations 
(Figure 2). MDS model estimates generally fell within annual NSDUH 95% confidence 
intervals. Both NSDUH and MDS model data show expected declines in smoking 
prevalence over this time period. The 2016-2018 increase in current MD incidence among 




Figure 2. Smoking prevalence among US adults with current and never MD, 
calibrated model vs. NSDUH of 2005-2018 
 
Comparison of adult smoking prevalence estimates between survey data and the 
calibrated model. Dots with vertical lines = NSDUH estimates of current smoking 
among adults with current MD with confidence intervals; triangles with vertical lines 
= NSDUH estimates of current smoking among adults with never MD with 
confidence intervals; solid lines = model estimates for adults with current MD; 





Under a status quo scenario, all populations experience decreasing smoking prevalence 
over time (Table 1). Among those in the model who have no history of MD, smoking 
prevalence is projected to decrease from 16.2% to 7.5% for females and from 22.3% to 
11.0% for males between 2018 and 2060, representing a 56% and 51% relative decrease 
respectively (-8.7 and -11.3 percentage points in absolute terms). By comparison, adults 
with current MD have consistently higher smoking rates during this period, with female 
prevalence declining from 29.3% to 19.6% (33% relative decrease; -9.7 percentage 
points) and male prevalence from 34.3% to 26.6% (22% relative decrease; -7.7 
percentage points).  
The model estimates that 483,579 SADs will occur among people with current MD from 
2018 to 2060, 59% among men. The number of annual SADs is expected to decline from 
16,167 in 2018 to 9,407 in 2060. In 2018, smoking-attributable deaths represent 16.5% 
and 27.7% of all deaths among women and men with MD, higher than for women and 
men without a history of MD for whom SADs represent 9.8% and 24.8% of all population 
deaths. By 2060, SADs will represent 7.6% and 15.2% of all deaths among women and 
men with MD, compared to 5.6% and 11.6% among women and men without a history of 
MD. However, uncertainty analyses for this metric show that estimates overlap with each 
other (Appendix Table S5). From 2018-2060, approximately 11.3 million cumulative life 
years would be lost among adults with current MD, even as smoking declines and the 
estimated number of life years lost drops each year. Under an MPRPM scenario in which 
no new initiation occurs and 100% of smokers quit in 2018, including those at younger 
ages, 7.5 million life years would be gained, representing 66% of those lost under current 
conditions. Of all SADs expected, 264,000 (55%) could be avoided under this best-case 
scenario (Figure 3).  
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Table 1. Smoking-attributed mortality and life-years lost among US adults with current and never MD, 2018-
2060   
Males 
Current MD Never MD Total population 
2018 2060 2018 2060 2018 2060 
Smoking prevalence (%) 34.3 26.6 22.3 11.0 23.4 13.9 
Proportion of all deaths 
attributed to smoking (%) 
27.7 15.2 24.8 11.6 25.0 12.0 
Annual number of deaths 9,339 6,264 327,807 148,555 357,628 169,653 
Cumulative number of 
deaths 
9,339 285,238 327,807 10,082,538 357,628 11,021,055 
Annual years of life lost 221,026 158,512 4,817,050 1,708,241 5,498,403 2,224,591 
Cumulative years of life lost 221,026 6,764,096 4,817,050 129,461,482 5,498,403 150,959,311 
Females 
Current MD Never MD Total population 
2018 2060 2018 2060 2018 2060 
Smoking prevalence (%) 29.3 19.6 16.2 7.2 18.6 10.4 
Proportion of all deaths 
attributed to smoking (%) 
16.5 7.6 9.8 5.6 10.5 6.0 
Annual number of deaths 6,828 3,143 101,783 55,352 123,205 65,847 
Cumulative number of 
deaths 
6,828 198,341 101,783 3,599,059 123,205 4,240,851 
Annual years of life lost 164,503 71,910 1,488,729 526,912 1,994,722 760,031 
Cumulative years of life lost 164,503 4,497,855 1,488,729 43,444,689 1,994,722 57,644,928 
 
Summary table of model projections for adult males and females with a past year major MD episode (current MD), 
no lifetime history of an MD episode (never MD), and the total population. Current smoking is defined as smoking at 




Figure 3. Cumulative smoking-attributable deaths and years of life lost among US 
adults with MD, 2018-2018. 
 
Model projections of the cumulative number of smoking-attributable mortality and life 
years lost among the adult population with a past year MD episode. SAD = Smoking-
attributable death; YLL = years of life lost; MPRPM = Maximum potential reduction in 
premature mortality scenario in which all smokers with MD quit smoking and no new 
smoking initiation occurs starting in 2020. Shaded yellow ribbons represent SADs and 





The prevalence ratio comparing smoking among adults with current MD with adults who 
have never had MD is projected to increase over time (Figure 4). Sensitivity analyses 
show that this general increase in the prevalence ratio is consistent across parameter 
combinations. In 2018, women with MD were 1.81 (LHS range: 1.64 - 2.09) times as likely 
to be smokers compared to those without a history of MD; by 2060, the female smoking 
prevalence ratio reaches 2.73 (LHS range: 2.43 - 3.37). For men the ratio is 1.54 (LHS 
range: 1.38 – 1.71), rising to 2.42 (LHS range: 2.13 – 2.73) by 2060.  
 
Figure 4. Smoking prevalence ratio between adults with current and never 
MD, 2018-2060 
 
Female (red) and male (blue) model projections for the smoking prevalence ratio 
between adults with a past year MD episode (current MD) and adults who have 
never had an MD episode in their lifetime (never MD). Current smoking is defined 
as smoking at all within the past year. Transparent red and blue ribbons 
represent optimum range values generated from Latin hypercube sampling 





We developed a simulation model of smoking and MD comorbidity to evaluate smoking 
prevalence, smoking-attributable mortality and life-years lost among US adults with MD. 
In the absence of intervention, our model projects that 484,000 adults with current MD 
will die prematurely as a result of their smoking with 11.3 million life years lost from 2018-
2060. Although people with current MD make up a small segment of the US adult 
population (females: 8.9%; males: 5.4%), MD is the most prevalent mental disorder—thus 
they constitute a large segment of smokers with any mental illness. Depression remains 
one of the largest contributors to the global burden of disease and disability.38 Among 
those with MD, a large proportion smoke, which further increases risk of disability and 
disease.  
Despite overall decreases in smoking prevalence, our model shows that the smoking 
prevalence ratio by MD status will widen over time, even under optimistic parameter value 
assumptions. Though this metric suggests a widening of the disparity with time, adults 
with MD would still experience larger absolute declines in smoking prevalence compared 
to those who have never had MD—a reflection of their higher initial starting point. For 
instance, from 2018-2060 smoking prevalence among women with current MD would 
decrease by 9.7 percentage points compared to 8.7 percentage points among women 
with never MD.  
Although the smoking prevalence ratio between women with and without MD is greater 
than for men, the proportion of smoking-attributable deaths is still larger for men. Gender 
differences in attributable deaths are driven by both the higher prevalence of smoking 
among men and the higher prevalence of depression among women. More than 1 in 4 
deaths among men and approximately 1 in 6 among women with MD are smoking-
attributable. This statistic is more stark for adults with serious psychological distress, who 
smoke at even higher rates than people with MD—roughly 1 in 3 of their deaths is 
smoking-attributable.39  
Study limitations and strengths 
This is the first joint model of smoking and MD comorbidity in the U.S. It integrates the 
best available data sources on US smoking and depression patterns. First, the underlying 
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sub-model uses re-scaled CISNET smoking initiation and cessation inputs that reflect 
historical patterns by age, gender, and birth cohort. Second, for trend assessment we use 
the NSDUH, the only nationally representative dataset with consecutive years of data on 
depression and smoking. While we calibrated the model to 14 years of observed data, 
the CISNET smoking inputs were generated using the National Health Interview Surveys 
for 1965-2018. We leverage over five decades worth of historical patterns from the NHIS, 
while fitting the model to contemporary NSDUH data specific to people with MD. Third, 
depression parameters are from the nation’s longest-running psychiatric epidemiological 
survey, the Baltimore Epidemiological Catchment Area (ECA) Follow-up Study, re-scaled 
and calibrated to the NSDUH.19  
This model does not consider e-cigarette use, which has risen dramatically, especially 
among youth and young adults.40-42 Unfortunately the NSDUH does not include questions 
about use of e-cigarettes or other electronic nicotine delivery systems (ENDS). This 
model offers a baseline scenario for comparison with future scenarios in which patterns 
of ENDS use influence smoking use and disparities by mental health status. The rising 
popularity of ENDS among smokers could have a positive impact on the population with 
mental health conditions if ENDS facilitate quitting, and on disparities if they do so at 
higher levels for this group compared to those without mental health conditions. This 
model also assumes smoking rates remain constant by age, period, and birth cohort going 
forward. However they may decline even more, which would further decrease expected 
smoking-attributed mortality in the population. 
Larger trends beyond the 14-year period of calibration may not be captured by the current 
model. A recent study found depression prevalence rising for specific subgroups, 
including youth ages 12-17.43 The NSDUH data in our analysis show increasing MD  
among young adults ages 18-25.29 If MD incidence rates are increasing over time, our 
results are likely to underestimate the true burden of depression in the population, and 
thereby the extent of smoking-attributable mortality among those with depression. 
Changing depression patterns could affect our estimates of smoking-attributable mortality 
in the model; we assume that MD incidence rates for young adults remain constant at 
their 2018 levels, but if they revert back to their pre-2016 levels, the mortality burden of 
MD would decrease (See Appendix Table S6).  
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We do not account for other sociodemographic factors associated with both smoking and 
MD. For example, disparities in smoking by MD status are even more prominent when 
considering differences by socioeconomic status.44 The current model does not 
disaggregate the population beyond age and gender, because introducing too much 
population heterogeneity can dramatically increase the number of unique states in the 
model, leading to ‘state explosion’.45 It would be problematic to calibrate a model with a 
large number of states to survey data when small numbers in specific subgroups would 
also lead to unstable estimates (e.g., wide confidence intervals).  
Moreover, the model simplifies aspects of the individual history of depression to capture 
patterns at the population-level. For example, we do not examine duration or frequency 
of depressive episodes at the individual-level.  
Our data sources do not survey the homeless, imprisoned, or institutionalized 
populations, where both smoking and MD are highly prevalent.46 While absolute 
projections from the model cannot be generalized to these groups, the relative trends may 
still be applicable for people with other behavioral health conditions. MD is often comorbid 
with other psychiatric disorders; this analysis does not evaluate MD effects independent 
of other mental disorders. If these groups were included, the burden of both smoking and 
MD in the US population, and the smoking disparity by MD status, would likely be much 
larger. 
The absence of other data sources that assess both smoking and MD prevents 
comparison of the model predictions with external historical data; external model 
validation would increase confidence in our results. Still, the model outputs corroborate 
existing research showing the potential for the burden of tobacco to continue 
disproportionately affecting people with mental illness even as the population experiences 
declines in smoking prevalence.47-49  
Conclusions 
Disparities in smoking by mental health status are likely to persist unless major changes 
to the policy and treatment environment are implemented. We modeled an ideal MPRPM 
scenario, the benefits of which will not come close to being realized unless bold, 
comprehensive tobacco control policies are pursued in tandem. Despite long-standing 
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recommendations, only 38% of US mental health treatment facilities offer tobacco 
cessation counseling.50 Evidence shows that public education campaigns that feature 
smokers with depression can increase quit attempts among smokers with mental health 
conditions as well.51,52 Tobacco product regulations that reduce the nicotine content in 
cigarettes to non-addictive levels could help smokers with mental health conditions to 
quit.53,54 ENDS present a reduced-risk alternative that could improve the health of 
comorbid smokers if used instead of cigarettes by those who are otherwise unwilling or 
unable to quit.55 While these strategies could collectively narrow the cessation disparity,3 
interventions that address smoking initiation among people with mental health conditions 
would lead to even larger mortality reductions in the long-run.  
This simulation model offers decision-makers a potential view of the future in the absence 
of meaningful intervention. The model can also be adapted to evaluate and compare the 
potential public health impacts of various tobacco control strategies on the MD population. 
This study advances MD research by focusing on its comorbidity with smoking, and 
placing it in the context of life expectancy. Given the bidirectional nature of this 
relationship, if smoking cessation can improve depressive symptoms,8,12,56 this could 
furthermore reduce MD prevalence; improving prevention and treatment of MD could 
likewise reduce harms from smoking—areas for future research. 
The US is not alone in having high smoking rates among those with mental health 
conditions;57 other countries with different environments for mental health care and 
tobacco control could similarly benefit from similar models.58 Future research can explore 
the population-level impact of large-scale tobacco control interventions that promote 
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